Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human choric gonadotrophin dependent

Joseph Neulen1,8, Sonja Raczek2, Martin Pogorzelski2, Klaus Grunwald1, T.K.Yeo3, Harold F.Dvorak4, Herbert A.Wech4 and Meinert Breckwoldt2

1Department of Gynaecology, Endocrinology and Reproductive Medicine, University Clinic RWTH D-52074 Aachen, 2Universitat Frauenklinik, D-79106 Freiburg, Germany, 3Beth Israel Hospital, Harvard Medical School, Boston, MA, USA and 4Gesellschaft für Biotechnologische Forschung, D-38124 Braunschweig, Germany

© European Society for Human Reproduction and Embryology 1998

Introduction

Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) occurs in different forms. Molecular cloning reveals the existence of five subtypes of VEGF/VPF that are generated by alternate splicing (Ferrara et al., 1990; Dissen et al., 1993). VEGF/VPF165 is the most abundant form of this growth factor inducing endothelial cell proliferation as well as angiogenesis in vivo and increases capillary permeability. Here we report the expression of VEGF/VPF mRNA by cultured human luteinized granulosa cells (GC) for at least 10 days. Without HCG VEGF/VPF expression declined after day 4 and by day 10 was reduced to ~30% of the value at day 4. However, after culture in the presence of 1 U/ml human chorionic gonadotrophin (HCG), expression of VEGF/VPF mRNA by GC was four times greater than control experiments by day 10, and increased 100% from day 4 to day 10. Simultaneously, HCG supplementation increased VEGF/VPF secretion by GC. Medium VEGF/VPF on day 3 was 13 pM without and 11 pM with HCG. Medium VEGF/VPF on day 10 was 6 pM without HCG and 29 pM with HCG. These results suggest that vascularization of the corpus luteum is induced by HCG-mediated effects of VEGF/VPF.

Key words: granulosa cells/ovarian hyperstimulation syndrome/vascular endothelial growth factor/vascular permeability factor

Materials and methods

Luteinized GC were obtained from 11 women undergoing oocyte retrieval for in-vitro fertilization. Reasons for infertility were tubal occlusion (seven couples), male factor infertility (three couples), and ‘unexplained infertility’ (one couple). Written consent was obtained and the experimental design was approved by the local ethics committee. Mean age of these patients was 31.1 years (range: 24–38 years). In these patients, multiple follicular development was achieved.

Vascularization and adequate blood flow are essential requirements for normal corpus luteum function (Carr et al., 1981; Jones, 1991; Richardson et al., 1992). In rats, diabetic vessel damage was shown to lead to reduced progesterone production and consequently to an inadequate endometrial transformation (Garris, 1988). Changes in peak systolic blood flow velocity demonstrated by ultrasound techniques have been suggested as a useful monitor of corpus luteum function (Alcazar et al., 1996; Bourne et al., 1996).

Abundant VEGF/VPF generation, however, is reported to elicit ovarian hyperstimulation syndrome, a severe complication of the use of ovarian stimulation in infertility treatment (McClure et al., 1994; Neulen et al., 1995).

This study was designed to demonstrate secretion of VEGF/VPF by human GC in vitro and to describe the effects of HCG on VEGF/VPF gene expression and secretion by GC during extended culture.
with pure follicle stimulating hormone (FSH) (225 IU per day; Fertinorm HP®; Serono, Munich, Germany) until follicular maturity. Gonadotrophin therapy was preceded by complete desensitization of the pituitary gland with 0.1 mg per day of triptorelin (Decapeptyl®; Ferring, Kiel, Germany). Mean total FSH dose administered per patient was 2025 IU (range: 1125–2925 IU). An average of eight follicles >13 mm per patient were induced (range: four to 17 follicles). For ovulation induction 10 000 IU HCG (Pregnesin®; Serono, Munich, Germany) were injected 36 h prior to ultrasound-guided transvaginal follicle aspiration. Before ovulation induction mean oestradiol concentrations were determined in the range of 3.2–14.7 nM.

Granulosa cell preparation and culture conditions were as described (Neulen et al., 1995). Culture was continued for 10 days. To study the effects of HCG, medium was supplemented with 1 IU/ml HCG continuously during cell culture. Media were completely replaced by fresh media at day 3, 5, 7 and 10, and the removed media were used for VEGF/VPF quantification (seven individual cell cultures). For slot blot analysis cells were harvested after 4, 7 and 10 days of culture (four individual cell cultures). In the remaining cell cultures media were replaced after the indicated time intervals.

For slot blot determination, total cellular RNA from GC was prepared by acid guanidinium thiocyanate–phenol–chloroform extraction and hybridization was performed under stringent conditions as described elsewhere (Weindel et al., 1992). Specificity of the VEGF/VPF gene probe has been previously demonstrated by Northern blotting (Yan et al., 1993). After autoradiogram laser densitometry of slot blots, VEGF/VPF expression rates were related to Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) expression which is expected to be constant. Experiments were repeated four times.

VEGF/VPF concentrations were determined in culture media by DELPHIA technique as described by Yeo et al. (Yeo et al., 1992) employing polyclonal rabbit VEGF/VPF antibodies.

Values were compared by Student’s t-test for unpaired data.

All chemicals were obtained from Sigma, Deisenhofen, Germany.

Results
Slot blot analysis showed that VEGF/VPF gene expression in GC was ~4-fold enhanced after 7 and 10 days by culture in the presence of continuous HCG stimulation when compared to control cultures [four individual cell cultures; P < 0.05 (control versus 1 U HCG/ml medium at day 7 and day 10)]. VEGF/VPF expression increased 100% from day 4 of culture to day 10 in the presence of 1 U/ml HCG. After only 4 successive days of treatment with HCG there was no difference in VEGF/VPF gene expression between HCG-treated and control GC.

In control GC VEGF/VPF gene expression declined by day 10 to ~30% of the value on day 4 (Figures 1 and 2).

GC secreted VEGF/VPF into the culture medium. In control GC cultures VEGF/VPF concentrations decreased from 13 pM on day 3 to 6 pM by day 10. In cultures supplemented with 1 U/ml HCG VEGF/VPF concentrations increased to 27 pM at day 7 and 29 pM at day 10 [P < 0.01 (control versus 1 IU HCG/ml medium); seven individual GC] (Figure 3).

Discussion
The data presented here demonstrate that HCG augments the VEGF/VPF mRNA content of human GC during extended cell culture. Moreover, HCG enhanced VEGF/VPF secretion by human GC simultaneously.

Thus, the physiological angiogenesis which occurs during corpus luteum formation represents another effect mediated by HCG. It appears that not only is steroidogenesis supported by exogenous or endogenous trophoblastic HCG, but also that anatomical differential and functioning of the corpus luteum are regulated by this hormone.

The data suggest that HCG effects on VEGF/VPF production are maintained for a prolonged period. Lack of HCG causes GC depletion of VEGF/VPF. It can be assumed that vascularization
remains inadequate in corpora lutea without sufficient HCG or luteinizing hormone (LH) support.

Recent experiments (Neulen et al., 1995) demonstrated in cultured human GC that interruption of HCG supplementation for 72 h resulted in an intensified response of GC to HCG. 1 U/ml HCG increased VEGF/VPF mRNA expression after 72 h in culture. In those cells specific HCG binding could be confirmed. In the experiments reported here the culture conditions were changed to continuous HCG supplementation in vitro, and this led to a prolonged insensitivity to HCG which prevailed for at least 4 days. In vivo, primate corpus luteum responsiveness to HCG depends upon luteal age (Benyo et al., 1993). HCG causes an increase in luteal progesterone production after ovarian stimulation during the mid-luteal and late luteal phases, but not at the early luteal phase (Auletta et al., 1995; Saunders et al., 1996). In our experiments the effects of HCG on VEGF/VPF gene expression and secretion in vitro could be confirmed after only 4 days of continuous HCG exposure. Culture in the absence of HCG supplementation appeared to sensitize GC towards HCG stimulation.

A previous paper (Yan et al., 1993) demonstrated that the VEGF/VPF mRNA expression by GC from individual patients was highly variable, despite similarities of their oestradiol concentrations and number of follicles.

Physiologically, VEGF/VPF effects have been suggested to initiate vascular growth into the corpus luteum and to maintain vascular support. Production and secretion of VEGF/VPF by luteinized GC are regulated by LH or HCG.

With an increase in the mass of GC and/or intensified sensitivity towards LH/HCG, larger amounts of VEGF/VPF become effective, resulting in conditions analogous to ovarian hyperstimulation syndrome (OHSS). In urine samples obtained from patients undergoing ovarian stimulation for infertility treatment during the corpus luteal phase VEGF/VPF concentrations rose above the values seen in the pre-ovulatory phases (Robertson et al., 1995). This increase was accentuated in patients developing ovarian hyperstimulation syndrome. Accordingly, VEGF/VPF concentrations in serum from patients with OHSS were greater than those from healthy women (Krasnow et al., 1996). VEGF/VPF provokes capillary leakage resulting in massive third space fluid accumulation (Rabau et al., 1967; Senger et al., 1983). Ascites from patients with OHSS contains large amounts of VEGF/VPF (McClure et al., 1994). VEGF/VPF stimulates secretion of von Willebrand factor (vWF) in vascular endothelial cells (Brock et al., 1991).

In serum from patients with OHSS very high concentrations of VEGF/VPF were observed (Todorow et al., 1993). These results indicate that during corpus luteum activity high amounts of VEGF/VPF are produced, the quantity being dependent, to some extent, on the number of luteinized GC. It can be assumed that human GC are a major source of VEGF/VPF production and secretion (Yan et al., 1993; Neulen et al., 1995). These results suggest that in GC VEGF/VPF production might not be regulated by product inhibition. Therefore, high HCG concentrations provoke even greater production of VEGF/VPF. Consequently, patients with multiple pregnancies are at higher risk for OHSS than patients with singleton pregnancies (Mathur et al., 1995).

Two major groups of patients suffering from OHSS can be distinguished. Some patients will develop OHSS immediately after follicular puncture and embryo transfer irrespective of whether a pregnancy is achieved or not. Another group of patients will develop OHSS only at ~7 days after follicular puncture, around the time of embryo implantation (Manaka et al., 1995). There is obviously a higher risk of developing severe OHSS during early pregnancy (McClure et al., 1992; Morris et al., 1995). Since early onset of OHSS is probably elicited by exogenous HCG application it can be avoided by lowering the HCG dosage or by replacing it by GnRH analogues for ovulation induction (Shalev et al., 1994; Brinsden et al., 1995). Late onset OHSS, however, is provoked by endogenous HCG of trophoblastic origin due to an exponential increase in HCG (Zalel et al., 1995).

The impact of HCG on GC can persist until the corpora lutea become insensitive to HCG, after the ninth week of gestation. Accordingly, in clinical studies OHSS symptoms gradually diminish after the first trimester of pregnancy (Marpail et al., 1992; Benifla et al., 1994).

The present data are in accordance with a growing body of evidence that VEGF/VPF may represent a significant pathophysiological promoter for OHSS.

Acknowledgements

Supported by the Deutsche Forschungsgemeinschaft Grant Ne 388/4-1.

References


